Repligen Shares Rise After 2Q Adj EPS Beats Estimates
Dow Jones2026/07/28 16:05By Grace Yoon
Shares of Repligen rose after the life sciences company's second quarter adjusted earnings per share and revenue beat estimates.
The stock was up 16% to $152.02 in recent trading. Despite the intraday gains, shares are down 7.3% since the start of the year.
Repligen posted net income of $5.01 million, or 9 cents a share, compared with $14.87 million, or 26 cents a share, a year earlier. Adjusted income from operations was $34 million compared with $22 million.
Adjusted earnings per share were 54 cents a share. Analysts polled by FactSet expected 45 cents a share.
Revenue rose 12% to $204.1 million. Analysts polled by FactSet expected $206.1 million.
The company forecast fiscal 2026 revenue between $813 million and $835 million and earnings per share between $2.03 and $2.09. Analysts polled by FactSet are expecting revenue of $822.5 million and earnings per share of $1.10.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
July 28, 2026 12:05 ET (16:05 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin's Weirdest Trader Yet? Fly Brain Makes a Profit
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <MAMK.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Crypto prices
More
